CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-Label, Single-Arm, Multicenter, Dose-Escalation and Dose-Expansion Phase 1/2I/II Study for the Safety, Tolerability and Preliminary Efficacy of MDSY-1240, a STAT3 Degrader, in Participants With Hematologic Malignancies and Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07899632
Title field or adapter rule: {'original_value': 'An Open-Label, Single-Arm, Multicenter, Dose-Escalation and Dose-Expansion Phase 1/2I/II Study for the Safety, Tolerability and Preliminary Efficacy of MDSY-1240, a STAT3 Degrader, in Participants With Hematologic Malignancies and Advanced Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:30.149585+00:00
Published At: 2026-10-27T00:00:00+00:00
Record Updated At: 2026-10-27
Source Retrieved At: 2026-10-31T22:18:28.651351+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Triple-Negative Breast Cancer (TNBC)", "Gastric Cancer (GC)", "Gastric Cancer Adenocarcinoma Metastatic", "Ovarian Cancer Metastatic", "Ovarian Cancer Metastatic Recurrent", "Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)", "Hepatocellular Carcinoma Metastatic", "Classical Hodgkin Lymphoma Relapsed", "Cutaneous T-Cell Lymphoma/Mycosis Fungoides", "Cutaneous T-Cell Lymphoma/Sezary Syndrome", "Cutaneous T-Cell Lymphomas", "Peripheral T-cell Lymphoma (PTCL)", "Large Granular Lymphocytic Leukemia (LGL-L)", "T-Cell Large Granular Lymphocytic Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-27", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07899632"
protocolSection.identificationModule.officialTitle: "An Open-Label, Single-Arm, Multicenter, Dose-Escalation and Dose-Expansion Phase 1/2I/II Study for the Safety, Tolerability and Preliminary Efficacy of MDSY-1240, a STAT3 Degrader, in Participants With Hematologic Malignancies and Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['MDSY-1240 Dose Escalation', 'MDSY-1240 Dose Expansion'], 'description': 'Participants will receive MDSY-1240 Intravenously (IV) on days 1, 8, 15, and 22 in a 28-day cycle.', 'name': 'MDSY-1240', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.